Research & Development

Our commitment to research and development at Getwell transcends traditional boundaries, particularly in the realm of sterile oncology drugs, where we emphasize the revolutionary potential of Novel Drug Delivery Systems.

Better Science, Better Life: Pioneering R&D in Oncology at Getwell

At Getwell, our dedication to “Better Science, Better Life” propels our pioneering research & development efforts in oncology. This guiding principle shapes our commitment to advancing innovative research paradigms and leveraging cutting-edge technologies, all with a patient-centric focus. Our collaborative approach, engaging with leading research institutions and healthcare professionals, underscores our commitment to a future where our R&D initiatives redefine possibilities and usher in a better life for individuals impacted by cancer.

Vision for Impact

As we forge ahead, “Better Science, Better Life” is not merely a slogan but a driving force behind our mission. Our goal is to translate scientific breakthroughs into tangible improvements, offering innovative therapies and reshaping the landscape of cancer care. Envisioning a future where our contributions to oncology R&D bring about meaningful change, we are dedicated to making a lasting impact on the lives of cancer patients, embodying the transformative power of better science for a better life.

Current Areas of Focus

Targeted therapies: Liposomes and Nanoparticles based formulations

I-Dox and Nanopac

Pipeline product:-

Irinotecan Liposomal Injection

Improving drug formulations to reduce reconstitution errors by making them Ready-to-use/Dilute

Taxewell-RTU

Pipeline product:-

Cyclophosphamide Injection 500mg/2.5ml, 1gm/5ml
Bendamustine Hcl Inj 25mg/1ml, 100mg/4ml
Pemetrexade Inj 100mg/4ml, 500mg/20ml

Guided by a visionary philosophy, our R&D endeavours are propelled by a dual mission: to elevate therapeutic outcomes for cancer patients and to contribute to the progressive landscape of oncology treatments.